| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -5,657,137 | -7,922,733 | -4,151,845 | -7,283,640 |
| Amortization | NaN | 0 | 0 | 1,779 |
| Stock-based compensation | 1,544,214 | 2,170,683 | 1,544,214 | 3,088,428 |
| Accounts payable | -365,461 | 2,140,193 | -187,590 | 118,940 |
| Deferred compensation | NaN | 367,538 | NaN | NaN |
| Unreimbursed expenses (accrued) | -224,114 | 69,662 | 123,982 | 6,936 |
| Net cash used in operating activities | -4,702,498 | -3,174,657 | -2,671,239 | -4,067,557 |
| Sale of common stock via private placement, net of costs | NaN | NaN | NaN | 0 |
| Sale of common stock via atm program, net of costs | 9,029,912 | 5,545,700 | 3,208,116 | 3,100,668 |
| Net proceeds from exercise of remaining underwriter warrants | NaN | 0 | 145,000 | NaN |
| Net cash provided by financing activities | 9,029,912 | 5,545,700 | 3,353,116 | 3,100,668 |
| Net increase (decrease) in cash | 4,327,414 | 2,371,043 | 681,877 | -966,889 |
| Cash, beginning of period | 6,178,021 | 3,806,978 | 4,091,990 | NaN |
| Cash, end of period | 10,505,435 | 6,178,021 | 3,806,978 | NaN |
Greenwich LifeSciences, Inc. (GLSI)
Greenwich LifeSciences, Inc. (GLSI)